[go: up one dir, main page]

ATE431157T1 - Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie - Google Patents

Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie

Info

Publication number
ATE431157T1
ATE431157T1 AT03814397T AT03814397T ATE431157T1 AT E431157 T1 ATE431157 T1 AT E431157T1 AT 03814397 T AT03814397 T AT 03814397T AT 03814397 T AT03814397 T AT 03814397T AT E431157 T1 ATE431157 T1 AT E431157T1
Authority
AT
Austria
Prior art keywords
taxol
sensory neuropathy
induced sensory
induced
treating
Prior art date
Application number
AT03814397T
Other languages
English (en)
Inventor
David Shelton
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Application granted granted Critical
Publication of ATE431157T1 publication Critical patent/ATE431157T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
AT03814397T 2002-12-23 2003-12-23 Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie ATE431157T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43614702P 2002-12-23 2002-12-23
PCT/US2003/041367 WO2004058190A2 (en) 2002-12-23 2003-12-23 Methods for treating taxol-induced sensory neuropathy

Publications (1)

Publication Number Publication Date
ATE431157T1 true ATE431157T1 (de) 2009-05-15

Family

ID=32682348

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814397T ATE431157T1 (de) 2002-12-23 2003-12-23 Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie

Country Status (10)

Country Link
US (1) US20050089521A1 (de)
EP (1) EP1581759B1 (de)
JP (1) JP2006513187A (de)
AT (1) ATE431157T1 (de)
AU (1) AU2003300397A1 (de)
CA (1) CA2511295A1 (de)
DE (1) DE60327655D1 (de)
ES (1) ES2326080T3 (de)
NZ (1) NZ540879A (de)
WO (1) WO2004058190A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
CN1947012A (zh) * 2003-12-23 2007-04-11 瑞纳神经科学公司 激动剂抗－trkC抗体和使用其的方法
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) * 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) * 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0730740T3 (da) * 1993-11-23 1998-09-28 Genentech Inc Kinasereceptoraktiveringsassay
JPH09506250A (ja) * 1993-11-23 1997-06-24 ジェネンテク，インコーポレイテッド Ｒｓｅと命名される蛋白チロシンキナーゼ
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
PT912184E (pt) * 1996-06-25 2002-12-31 Cephalon Inc Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
WO2001098361A2 (en) * 2000-06-22 2001-12-27 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
AU2001286930A1 (en) * 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Also Published As

Publication number Publication date
NZ540879A (en) 2008-08-29
US20050089521A1 (en) 2005-04-28
EP1581759A4 (de) 2006-08-02
EP1581759B1 (de) 2009-05-13
JP2006513187A (ja) 2006-04-20
EP1581759A2 (de) 2005-10-05
CA2511295A1 (en) 2004-07-15
WO2004058190A2 (en) 2004-07-15
AU2003300397A1 (en) 2004-07-22
DE60327655D1 (de) 2009-06-25
WO2004058190A3 (en) 2005-03-10
ES2326080T3 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
EP1482962A4 (de) Verfahren zur behandlung von trx-vermittelten erkrankungen
ATE259245T1 (de) Verfahren zur behandlung von beweggungsstörungen
DE60335921D1 (de) Thrombusdetektor, vorrichtung zur behandlung von thromben und verfahren dafür
DE60120520D1 (de) Verfahren zur behandlung von abwasser
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
EP1635763A4 (de) Verfahren zur behandlung von neurodegenerativen erkrankungen
MEP31508A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ATE540681T1 (de) Verfahren zur behandlung von atherosklerose
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE411803T1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
EP1542702A4 (de) Verfahren und zusammensetzungen zur behandlung von neurologischen störungen
ATE278441T1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
EP1501511A4 (de) Verfahren zur behandlung von glaukom und anderen erkrankungen, die durch nos-2 expression vermittelt werden, durch hemmung des egfr-wegs
DE60334094D1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes
ATE431157T1 (de) Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE60229123D1 (de) Behandlung von fibromyalgie mit pindolol

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties